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Abstract
Since the identification of hepatitis C virus (HCV), viral sequencing has been important in understanding HCV classification,
epidemiology, evolution, transmission clustering, treatment response and natural history. The length and diversity of the
HCV genome has resulted in analysis of certain regions of the virus, however there has been little standardisation of
protocols. This systematic review was undertaken to map the location and frequency of sequencing on the HCV genome in
peer reviewed publications, with the aim to produce a database of sequencing primers and amplicons to inform future
research. Medline and Scopus databases were searched for English language publications based on keyword/MeSH terms
related to sequence analysis (9 terms) or HCV (3 terms), plus ‘‘primer’’ as a general search term. Exclusion criteria included
non-HCV research, review articles, duplicate records, and incomplete description of HCV sequencing methods. The PCR
primer locations of accepted publications were noted, and purpose of sequencing was determined. A total of 450 studies
were accepted from the 2099 identified, with 629 HCV sequencing amplicons identified and mapped on the HCV genome.
The most commonly sequenced region was the HVR-1 region, often utilised for studies of natural history, clustering/
transmission, evolution and treatment response. Studies related to genotyping/classification or epidemiology of HCV
genotype generally targeted the 59UTR, Core and NS5B regions, while treatment response/resistance was assessed mainly in
the NS3–NS5B region with emphasis on the Interferon sensitivity determining region (ISDR) region of NS5A. While the
sequencing of HCV is generally constricted to certain regions of the HCV genome there is little consistency in the
positioning of sequencing primers, with the exception of a few highly referenced manuscripts. This study demonstrates the
heterogeneity of HCV sequencing, providing a comprehensive database of previously published primer sets to be utilised in
future sequencing studies.
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Introduction
Given the difficulty in producing a continuous culture of the
hepatitis C virus (HCV), investigations of HCV have been
conducted mainly through the isolation and sequencing of the
virus from infected patients. From this sequence data, a great deal
has been learnt about the evolution of the virus within individuals,
variability across geographic locations, and correlations between
viral variation and clinical treatment response and disease
progression. The methods to obtain this sequence data, however,
have been largely diverse with little consensus in the sequencing
methods applied within the field. Standardisation of methodolo-
gies is important in maintaining a high level of reliability in
experimental output [1] and subsequent analysis [2,3], however, it
is more commonly undertaken in diagnostic testing than in the
research setting.
Systematic reviews are commonly used in biomedical,
epidemiology, public health and clinical research to provide
an exhaustive summary of literature relevant to a specific
research question, but are less common in the field of virology.
Systematic and general reviews of published data related to
sequencing of HCV have reported on genetic diversity [4], viral
evolution [5], transmission of HCV [6] and predictors of
treatment response or resistance [7], but there has been no
review of the sequencing methodologies used for HCV.
Considering the wide application of sequencing in investigating
HCV, our objective was to review HCV sequencing methodolo-
gies and to establish the variability of the regions sequenced. This
systematic review provides a library of primers and regions for
HCV sequencing, creating a valuable resource for other
researchers in the field of HCV. From this, it may be possible to
propose consensus regions that could be sequenced to increase the
comparability and dissemination of HCV sequencing data. A
systematic review of HCV sequencing is novel and similar
methodologies could be applied to other viruses to enhance
standardization and improve capacity for collaboration across
disciplines.
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Results
Study Selection
A search of the Medline (by PubMed) and SCOPUS scientific
databases identified 2099 publications with the selected keywords
(Figure 1). From this a total of 1727 were not suitable for further
analysis due to duplication of records (n = 563), being a review
article (n = 54), or insufficient methodological description or
irrelevance to HCV population sequencing (n = 1,046). This left
a total of 407 publications to be assessed, which increased to 450
following identification of a further 43 publications through back-
referencing. From these publications a total of 629 HCV
population sequencing amplicons with positions relative to the
H77 reference isolate [9] were identified.
Details of the selected publications including author list, title,
date of publication, and journal of all publications accepted,
selected primer sequence (where available) and 59- and 39-location
of primers (according to the H77-reference sequence using Los
Alamos National Laboratory Quick Align tool) are available in
Table S1. A position-weighted matrix score representing the
calculated nucleotide conservation in a 25 bp window as described
by Qiu et al [10] is available for each primer in Table S1 and
would allow for selection of primers with highly conserved
nucleotide sequences.
Study Characteristics
During analysis of the 450 publications the primary rationale for
sequencing was categorised as clustering/transmission, epidemiol-
ogy, evolution, genotyping/classification, natural history or
treatment response/resistance. HCV RNA sequencing was most
commonly performed for HCV genotyping/classification studies,
with 37% of all identified sequencing amplicons (Table 1). In
comparison, the remaining study groups each contributed between
9% and 17% of the amplicons identified. The median length of all
HCV population sequencing amplicons was 384 bp (Lower and
upper quartiles: 256, 592 bp), with treatment response/resistance
studies having a median amplicon size considerably larger than
other study groups. There were a number of sequencing amplicons
that were full length or near full length, being approximately
9,646 bp long, with very few amplicons between 3,000 and
8,000 bp long (Figure S1-a).
Description of HCV Population Sequencing
The regions of 59UTR-core, hypervariable region-1 (HVR-1)
and NS5B were the most commonly sequenced regions overall
and within most of the different types of studies sequencing the
HCV genome (Figure 2a). The exception was treatment response/
resistance studies where a majority of population sequencing
amplicons included the interferon sensitivity determining region
(ISDR) of NS5A. At a number of regions on the HCV genome
there was consensus on the positioning of the sequencing
amplicon, as can be seen at the HVR-1 and NS5B regions. A
position-weighted matrix score of viral diversity previously by Qiu
et al [10], where a score of 0 and a score of 2 represents 0% and
100% similarity respectively, demonstrates the variability of HCV
genome along its entire length (Black line in Figure 2a). When
aligned to the positioning of HCV sequencing amplicons it can be
seen that the highly conserved region of 59UTR region and a
moderately conserved segment in the NS5B gene were frequently
sequenced for genotyping/classification. In contrast, the most
genetically divergent portion of the HCV genome, being HVR-1,
was rarely used in genotyping/classification but regularly se-
quenced in other analyses, particularly evolution and natural
history.
As the positioning of sequencing/PCR primers would be
constricted by the variation in the viral genome, it could be
expected that there would be convergence in the design of these
primers. Further assessment of individual sequencing amplicons
reveals that while there is some degree of similarity in the
positioning of PCR/sequencing primers, the majority of sequenc-
ing amplicons are unique in size or positioning (Figure 2b – g). It
appears that it is more likely for sequencing amplicons to share
sequencing primer locations in the HVR-1 and NS5B locations,
but this may be influenced by the genetic variability, as seen by the
Qiu et al [10] conservation score at these locations. There were a
number of references to previously described sequencing primers
throughout the literature, although it was not uncommon to see a
59-primer from one method matched to a 39-primer from a
separate method (Table S1).
The number of published sequencing amplicons has decreased
consistently over the past 15 years. There was a rapid rise in the
number of publications between 1992 and 1996, peaking at 65
sequencing amplicons reported in that year (Figure S1-c). This was
followed by a large decline in the number of reported amplicons to
1999, and a slower decline between 2000 and 2010 ending with 12
sequencing amplicons reported in 2011. The greatest contributor
to the increase and subsequent decline was in the 1–500 bp sized
sequencing amplicons, whereas publication of 501–1000 bp and
greater than 1001 bp amplicons was relatively consistent over the
time period (Figure S1-b).
Discussion
In this systematic review of HCV population sequencing, there
was considerable heterogeneity in the regions sequenced along the
HCV genome. While there were examples of referencing to
previous studies, the majority of studies described novel sequenc-
ing primers or amplicons. This heterogeneity in amplicon
Figure 1. Flow diagram describing the review process and
study selection.
doi:10.1371/journal.pone.0067073.g001
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positioning may be a function of the high variability of the HCV
genome or due to differing hypotheses tested by independent
researchers. This study provides a comprehensive resource of
HCV population sequencing primers and amplicons covering the
entire HCV genome that may be used by future researchers across
disciplines. The application of systematically reviewing sequencing
data from other viruses with high genetic diversity (e.g. HIV)
would enhance the standardisation of regions analysed for various
study types and strengthen virological research in other fields.
There is clear consensus in the general positioning of
sequencing amplicons in particular regions of HCV, such as 59-
UTR, HVR-1 and ISDR, however, the precise location of primers
within these regions is not consistent. This diversity in primer
design may affect the output and comparability of data due to
differences in PCR/sequencing performance and bias [11],
potentially leading to conflicting findings. Consensus guidelines
for classification of new genotypes and subtypes [2,3] proposed
using either the entire genome or the Core/E1 and NS5B regions
of HCV to identify novel strains, with particular mention of a
segment of the NS5B gene first described by Enomoto et al [12].
As there are no guidelines for positioning of sequencing amplicons
in studies not examining genotype/classification researchers have
largely designed sequencing reactions independently, resulting in
inconsistent positioning of HCV sequencing amplicons.
Across the 9.6 kb genome of HCV, there were selected regions
that were more frequently sequenced than the rest of the genome:
specifically the 59-UTR, Core gene, HVR-1 and NS5B gene. A
rationale for HCV sequencing assigned to each study revealed that
the HVR-1 and NS5B regions were analysed in most of the study
types, whereas the 59-UTR and Core gene were predominately
sequenced in studies undertaking HCV genotyping and/or
classification. A segment of the non-structural 5A gene associated
with interferon sensitivity (ISDR) was most often sequenced in
studies assessing treatment response/resistance.
The development of directly acting antiviral agents (DAAs)
specific to HCV with high efficacy has raised concerns about the
potential for viral resistance mutations in the presence of these
agents. Previous studies have identified and reported sequence
[13] or amino acid [14] changes related to resistance phenotypes
that lead to viral rebound during antiviral treatment. As next
generation sequencing (NGS) and other novel technologies
develop, population sequencing will be less frequently utilised in
identifying these minor variants constituting a small percentage of
the viral population in an infected individual.
The positioning of amplicons for HCV population sequencing is
likely influenced by the high degree of variability of the virus
genome, and the functions of various segments of the virus. Studies
assessing response to standard interferon treatment may sequence
the ISDR of NS5A as amino acid mutations in this region have
been shown to correlate with treatment outcome in selected
patients [15]. Determining the genetic classification of HCV may
be performed using a number of regions (such as 59-UTR, Core
gene or NS5B gene) of the HCV genome that allow categorisation
of isolates with related types [16], while the HVR-1 of E2 gene
provides insight into the viral evolutionary responses at epitopes
exposed to the host’s immune system [17].
Since HCV was initially described there has been a rapid
increase in the number of studies utilising sequencing to analyse
the virus. Following the release of a proposed nomenclature for
HCV genotyping by Simmonds et al [2] there was a peak in the
number of sequencing reactions in 1996, followed by a decline
until 1999 and a steady number since. This decrease in reporting
of HCV sequencing may have resulted from the production of
commercial HCV genotyping methods, such as Inno-LiPA HCV
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Genotype 1 in 1996 [18]. The greatest reduction in reported
sequencing reactions was in the less than 500 bp category, with
relatively stable numbers of larger sized amplicons, potentially
reflecting the shift away from HCV sequencing as a genotyping
tool towards biological and functional analysis of the HCV virus
requiring longer amplicons.
This study has several limitations. The selection of studies for
this study included a search of PubMed and Scopus using HCV or
sequencing-specific keywords, resulting in more than 2000 studies
to review, of which over 75% were excluded based on evaluation
of content. The remaining studies were sorted into categories
according to the aim of the study. These processes were
undertaken manually and may have contributed to errors in the
selection and characterisation of the dataset. Studies relevant to
this systematic review may not have been identified if they did not
include the keyword terms used in the search, potentially resulting
in an underestimation of the overall number of studies describing
HCV sequencing. However, a large number of search terms were
used and additional studies were included through back-referenc-
ing.
This study provides the first reported review of population
sequencing methodology used in the HCV field, and provides a
comprehensive list of the population sequencing primers from
these studies. The review methodology in this study provides a
platform for further review and standardization of sequencing
methods undertaken in areas of research where high genetic
diversity may impact on the comparability of results, such as HIV,
hepatitis B virus and other infectious diseases. From the review of
the HCV sequencing amplicons, it was noted that there was great
heterogeneity in the positioning of population sequencing
amplicons in studies performed to date. This database of HCV
sequencing primers is a valuable resource for researchers in the
field of HCV that could be used to increase the comparability and
sharing of HCV sequencing data. The extensive heterogeneity of
the sequencing regions suggests potential for some standardisation
of regions analysed for each study type to strengthen future HCV
virological research.
Methods
This systematic review was written according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [8]. Given this statement was originally
developed for studies evaluating healthcare interventions, compo-
nents of this statement have been customized to fit the scope of the
current systematic review (Table S2).
Eligibility Criteria
All primary research papers that reported sequencing of the
HCV genome were included if they were:
(a) published in English; and
(b) conducted on human individuals.
Information Sources
A literature search of MEDLINE (PubMed) and SCOPUS was
performed on 11th December, 2011, covering all studies published.
The list of eligible articles found during the initial search was hand
searched for reference to sequencing of the HCV genome and
backward citation checks were carried out to identify further
potentially relevant studies. Review articles were not included in
this analysis.
Search Strategies
Medline Search (MeSH) terms were used to search for studies
relating to HCV ("Hepacivirus" OR "Hepatitis C Antibodies" OR
"Hepatitis C") and sequencing ("Cluster analysis" OR "Molecular
sequence data" OR "Base sequence" OR "Sequence Analysis" OR
"Molecular Epidemiology" OR "Sequence Homology" OR
"Sequence alignment" OR "Drug resistance") from these two
databases. The general search term ‘‘primer’’ was applied to
identify studies that utilised sequencing as a method as this term is
strongly related with PCR and sequencing.
Study Selection
The lists of studies from each search database were combined
and ineligible articles removed based on the following criteria:
duplicate reference, review article, abstract or title accessible only,
description of next generation sequencing (NGS) without popu-
lation sequencing, or not relevant/insufficient method description.
Studies were deemed eligible for this analysis if HCV population
sequencing with PCR/sequencing primer design or location was
described in the methodology section. Publications utilising
sequencing to confirm the accuracy of PCR products only were
excluded from the analysis, however those that performed
sequencing of a different region to validate a new method were
included.
Data Collection and Analysis
The genome location of HCV PCR/sequencing primers was
recorded for eligible studies, or back references noted where
methodology was described by other studies. For studies that
described a nested PCR protocol or specific sequencing primer the
innermost primer was used for the amplicon analysis. The
innermost primer pair was also selected where there were two or
more primer pairs covered an identical region, for example when
genotype-specific primer pairs were described. Where a sequenc-
ing region was derived from multiple overlapping sequencing
amplicons the outermost primers were selected at the 59- and 39-
primers respectively.
Eligible studies were categorised based on primary study focus
as either 1) Genotyping/classification, 2) Clustering/transmission,
3) Evolution, 4) Treatment response/resistance, 5) Epidemiology,
or 6) Natural history.
Supporting Information
Table S1 Database of HCV sequencing amplicons.
Including author list, title, date of publication, and journal of
Figure 2. Positioning of combined and individual sequencing amplicons along the HCV genome. Sequencing amplicons identified in
434 peer-reviewed studies were categorised into study types, and their location mapped along the length of the HCV genome (A). A measure of
genome diversity calculated by Qiu et al [10] illustrates the ranges of low and high genetic variation at regions frequently sequenced (e.g. 59-
untranslated region compared to 59-region of E2 gene). When viewed individually, the sequencing amplicons show the heterogeneity of sequencing
amplicon size and positioning for genotyping/classification (B), treatment response/resistance (C), clustering/transmission (D), natural history (E),
evolution (F) and epidemiology (G) study types.
doi:10.1371/journal.pone.0067073.g002
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accepted publications, selected primer sequence (where available)
and 59- and 39-location of primers.
(XLSX)
Table S2 PRISMA checklist.
(DOC)
Figure S1 Distribution of sequencing amplicons accord-
ing to size and year of publication. The size distribution of
HCV amplicons (A) shows a bias towards products smaller than
1000 bp in length, with fewer than 10% of amplicons being larger
than this. There is a rapid increase in the number of publications
until a peak in 1996. The decrease in reported sequencing
amplicons may be attributed to fewer amplicons sized 1–500 bp
(B) and a sharp drop in sequencing for genotyping/classification
from 1998 onwards. There were fluctuations in the numbers of
reported sequencing amplicons for all study types over the time
period (C).
(TIF)
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